This clinical-stage biopharmaceutical company has seen no estimate revision in the last 30 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s rally can turn into more strength down the road.
Kite Pharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
A better-ranked stock worth considering in the biomedical industry is Affymetrix Inc. (AFFX) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment